Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
Medical University of Vienna · Charité - Universitätsmedizin Berlin · +31 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
42
total citations
- FWCI
- 63.52
- Percentile
- 100%
- References
- 25
Citations per year
Authors
174- MDMaria De SantisCorresponding
Medical University of Vienna, Charité - Universitätsmedizin Berlin
- JPJoan Palou Redorta
Universitat Autònoma de Barcelona, Puigvert Foundation
- HNHiroyuki Nishiyama
University of Tsukuba
- MKMichał Krawczyński
Poznańska Hodowla Roślin (Poland)
- ASArtur Seyitkuliev
Saint-Petersburg Institute of History
Topics & keywords
Topics
Keywords
- Durvalumab
- Bladder cancer
- BCG vaccine
- Phase (matter)
- Phases of clinical research
No related works found for this paper.